Selling, General, and Administrative Costs: Perrigo Company plc vs Novavax, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Perrigo Company plc and Novavax, Inc. from 2014 to 2023. Perrigo, a stalwart in the industry, consistently outpaced Novavax in SG&A spending, reflecting its expansive operations and market reach. In 2023, Perrigo's SG&A expenses were approximately 2.7 times higher than Novavax's, highlighting its robust investment in administrative and sales functions. Notably, Novavax's SG&A expenses surged by over 2,200% from 2014 to 2023, indicating aggressive growth and expansion efforts. This financial narrative underscores the contrasting strategies of these companies, with Perrigo maintaining steady growth and Novavax rapidly scaling its operations. Such insights are invaluable for investors and industry analysts alike, offering a window into the strategic priorities of these pharmaceutical giants.